Monopar raises ~$91.9M net in offering; Wilson disease data published in Journal of Hepatology

Monopar Therapeutics

Offering of 1,034,433 shares at $67.67 and 960,542 pre-funded warrants at $67.669.
Net proceeds of ~$91.9M after deducting underwriting discounts and before expenses.
Agreed to repurchase 550,229 shares from Tactic Pharma (CEO's entity) at $63.6098 per share.
Journal of Hepatology letter shows ALXN1840 improved copper balance (p=0.005) in Wilson disease patients.
Offering expected to close September 25, 2025; share repurchase promptly thereafter.

item 1.01item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.